Taylor & Francis Group
Browse
idrd_a_1333173_sm0570.doc (5.82 MB)

Temperature-sensitive heparin-modified poloxamer hydrogel with affinity to KGF facilitate the morphologic and functional recovery of the injured rat uterus

Download (5.82 MB)
journal contribution
posted on 2017-06-02, 14:05 authored by He-Lin Xu, Jie Xu, Si-Si Zhang, Qun-Yan Zhu, Bing-Hui Jin, De-Li ZhuGe, Bi-Xin Shen, Xue-Qing Wu, Jian Xiao, Ying-Zheng Zhao

Endometrial injury usually results in intrauterine adhesion (IUA), which is an important cause of infertility and recurrent miscarriage in reproductive women. There is still lack of an effective therapeutic strategy to prevent occurrence of IUA. Keratinocyte growth factor (KGF) is a potent repair factor for epithelial tissues. Here, a temperature-sensitive heparin-modified poloxamer (HP) hydrogel with affinity to KGF (KGF-HP) was used as a support matrix to prevent IUA and deliver KGF. The rheology of KGF-HP hydrogel was carefully characterized. The cold KGF-HP solution was rapidly transited to hydrogel with suitable storage modulus (G′) and loss modulus (G″) for the applications of uterus cavity at temperature of 33 °C. In vitro release demonstrated that KGF was released from HP hydrogels in sustained release manner for a long time. In vivo bioluminescence imaging showed that KGF-HP hydrogel was able to prolong the retention of the encapsulated KGF in injured uterus of rat model. Moreover, the morphology and function of the injured uterus were significantly recovered after administration of KGF-HP hydrogel, which were evaluated by two-dimensional ultrasound imaging and receptive fertility. Not only proliferation of endometrial glandular epithelial cells and luminal epithelial cells but also angiogenesis of injured uterus were observed by Ki67 and CD31 staining after 7 d of treatment with KGF-HP hydrogel. Finally, a close relatively relationship between autophagy and proliferation of endometrial epithelial cells (EEC) and angiogenesis was firstly confirmed by detecting expression of LC3-II and P62 after KGF treatment. Overall, KGF-HP may be used as a promising candidate for IUA treatment.

Funding

This research was supported by National Natural Science Foundation of China (Grant Nos. 81603036, 81571392), Zhejiang Provincial Foundation for Health Department (Grant Nos. 2015ZDA023 and 2016KYA136), Zhejiang provincial program for the cultivation of high-level innovative health talents (Ying-Zheng Zhao), 151 talent project of Zhejiang province and 551 talent project of Wenzhou (Ying-Zheng Zhao), key support of high level talent innovation and technology project of Wenzhou (Zhao Ying-Zheng), Medicine Grant from Wenzhou Bureau of Science and Technology (Grant No. Y20160086), School Talent Start Fund of Wenzhou Medical University (Grant No. QTJ15020).

History